These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17275733)

  • 21. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
    Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
    Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state.
    Hornak V; Okur A; Rizzo RC; Simmerling C
    J Am Chem Soc; 2006 Mar; 128(9):2812-3. PubMed ID: 16506755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.
    Nalam MN; Ali A; Altman MD; Reddy GS; Chellappan S; Kairys V; Ozen A; Cao H; Gilson MK; Tidor B; Rana TM; Schiffer CA
    J Virol; 2010 May; 84(10):5368-78. PubMed ID: 20237088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
    Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
    J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
    Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
    Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
    Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
    Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the conformational landscapes of HIV protease structural ensembles using principal component analysis.
    Hassan S; Srikakulam SK; Chandramohan Y; Thangam M; Muthukumar S; Gayathri Devi PK; Hanna LE
    Proteins; 2018 Sep; 86(9):990-1000. PubMed ID: 30051500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H; Freire E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
    Seibold SA; Cukier RI
    Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity.
    Velazquez-Campoy A; Todd MJ; Freire E
    Biochemistry; 2000 Mar; 39(9):2201-7. PubMed ID: 10694385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
    Meher BR; Wang Y
    J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
    Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
    Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance.
    Scott WR; Schiffer CA
    Structure; 2000 Dec; 8(12):1259-65. PubMed ID: 11188690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
    Li D; Liu MS; Ji B; Hwang K; Huang Y
    J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
    Tzoupis H; Leonis G; Megariotis G; Supuran CT; Mavromoustakos T; Papadopoulos MG
    J Med Chem; 2012 Jun; 55(12):5784-96. PubMed ID: 22621689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
    Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
    Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.